SULT1A3 Inhibitors

SULT1A3 inhibitors can be broadly classified into several types: competitive inhibitors, allosteric inhibitors, and those affecting co-substrate affinity. Competitive inhibitors like Quercetin, Promethazine, and Acetaminophen operate by directly competing with the substrate for binding at the active site of the enzyme. They block the access of the substrate to the enzyme's catalytic machinery, thereby arresting the sulfonation process, which is the enzymatic function of SULT1A3. Sodium Salicylate is another interesting case, as it competes not for the substrate binding site but for the PAPS (3'-Phosphoadenosine-5'-phosphosulfate) binding site. By binding to this secondary site, Sodium Salicylate the co-substrate PAPS from binding, rendering the enzyme inactive.

Allosteric inhibitors, on the other hand, operate through an entirely different mechanism. Compounds like Genistein and Celecoxib bind to an allosteric site on SULT1A3, distinct from the active site. The binding of these molecules induces conformational changes in the enzyme structure, leading to a loss of catalytic efficiency. Another category includes inhibitors like Resveratrol and Salbutamol, which influence the enzyme's affinity for its co-substrate, PAPS. By altering this affinity, they modify the enzyme kinetics, leading to reduced enzymatic activity. It should be noted that inhibitors like Kaempferol and Estradiol can also directly interfere with the co-substrate PAPS, but they act more on the binding kinetics rather than altering the structure of the enzyme. Their actions can, therefore, be viewed as a hybrid of competitive and allosteric inhibition.